Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients
Key facts
- Who runs it
- Tang Ziren
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 350 people, planned
- Started
- 1 Jan 2022
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Butylphthalide and Sodium Chloride Injection
- Saline Solution
- Record updated
- 11 April 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (18)Hide the full registry criteria
Who can take part
- Age 18-80 years old
- Glasgow Coma Scale (GCS) scores ≤8 upon admission
- Return of Spontaneous Circulation (ROSC) ≥30min
- Signed the informed consent form
Who cannot take part
- Persistent cardiogenic shock that is unreversed (defined as a systolic blood pressure persistently <90mmHg despite treatment with fluid resuscitation, vasopressor agents, and inotropic medications)
- Presence of pre-existing cerebrovascular disease prior to cardiac arrest or confirmed intracranial hemorrhage by CT scan following admission
- Pre-existing CPC scores of 3-5 prior to cardiac arrest
- Prior use of NBP or any medication containing NBP before cardiac arrest
- History of prior drug or food allergies, or known allergies to the medication components used in this study
- Cardiac arrest due to irreversible causes such as trauma, poisoning, etc
- Cardiac arrest due to end-stage conditions such as advanced cancer
- Bradycardia or sick sinus syndrome occurs after ROSC
- Presence of severe bleeding tendency upon admission
- Other conditions deemed unsuitable for this trial by the principal investigator
- Presence of severe hepatic or renal dysfunction before cardiac arrest (defined as ≥3× upper limit of normal alanine transaminase or ≥2× upper limit of normal creatinine)
- Pregnant or lactating women, or reproductive-age females with elevated serum human Chorionic Gonadotropin (hCG) levels
- Existence of treatment limitations (patient or their legal representative refusing advanced life support treatment, including mechanical ventilation, chest compressions, targeted temperature management, etc.)
- Body temperature <30℃ upon admission
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Butylphthalide or cardiac arrest or neuroprotective drugs
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Cardiac arrest is one of the critical illnesses that is directly life-threatening, and patients who survive cardiac arrest develop severe neurological deficits or even die. The effectiveness of drugs to improve neurological function in resuscitated brain-injured patients has been a focus of research in the field of resuscitation. Butanephthalein has an ameliorating effect on the damage of central nervous function in patients with acute ischemic stroke, and can promote the improvement of patients' neurological deficits. On this basis, the present study was designed as a multicenter, prospective randomized controlled experiment, with internationally accepted methods for assessing near-term and long-term neurological function, to determine the effectiveness of butalbital in improving neurological function after cardiac arrest, with the aim of searching for new methods and ideas to improve neurological function and prognosis after cardiac arrest.
The 2 groups in the trial
- ButylphthalideTreatment being tested
Butylphthalide and Sodium Chloride Injection 100ml ivgtt bid 14days
Treatment: Butylphthalide and Sodium Chloride Injection
- Saline SolutionPlacebo, for comparison
Saline Solution 100ml ivgtt bid 14days
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neuroprotective Effect of Butylphthalide Injection on Patients With Return of Spontaneous Circulation After Cardiac Arrest:a Multicenter, Randomized Clinical Trial
- Criteria questions
- Built from NCT06572085, who can take part
- Record updated
- 11 April 2025